Acumen at Cantor Fitzgerald conference: sabirnetug, brain-shuttle push

At the 12th Annual Cantor Fitzgerald Global Healthcare Conference, Acumen Pharmaceuticals (ABOS) argued that its experimental drug sabirnetug offers a unique approach for treating Alzheimer's disease. Unlike currently approved amyloid-lowering therapies that target plaques, sabirnetug aims to reduce toxic amyloid beta oligomers, which the company believes could preserve synaptic function and yield faster cognitive benefits.

Phase I data from Acumen's INTERCEPT-AD study showed remarkable selectivity for oligomers (10,000-fold versus monomers) and promising biomarker changes. However, the company emphasized that the pivotal Phase II ALTITUDE-AD trial, enrolling 542 patients, will provide definitive results expected in Q4 2024. Management noted that a 30% or greater slowing in cognitive decline, along with competitive safety, would constitute a clear win.

Strategically, Acumen's focus on oligomers differentiates its program from existing therapies like lecanemab and donanemab, which target plaques. The company sees this as a distinct value proposition for both patients and physicians. While the near-term focus is on the positive Phase II readout, Acumen believes that demonstrating efficacy and biology through successful Phase II results could reshape perspectives on amyloid-directed treatments.